Theravance Biopharma, Inc. Operating Income Loss

• Theravance Biopharma, Inc. showed an increase of +92.3% in Operating Income Loss from 2024 to 2025.
• This data is from Theravance Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
• XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 14 years of available data (2012 to 2025), Theravance Biopharma, Inc.'s Operating Income Loss has grown by 62.4%.
• Historical annual values: Fiscal year 2025: -$3.60 million | Fiscal year 2024: -$46.95 million | Fiscal year 2023: -$56.04 million | Fiscal year 2022: -$91.96 million | Fiscal year 2021: -$257.78 million | Fiscal year 2020: -$297.63 million | Fiscal year 2019: -$251.92 million | Fiscal year 2018: -$238.75 million | Fiscal year 2017: -$260.12 million | Fiscal year 2016: -$180.47 million | Fiscal year 2015: -$181.90 million | Fiscal year 2014: -$232.54 million | Fiscal year 2013: -$156.28 million | Fiscal year 2012: -$9.58 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026